MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563390 | Name: Ness0327

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ness0327 is a potent cannabinoid CB1 receptor antagonist.

Chemical Structure

Ness0327
Ness0327
CAS#494844-07-4

Theoretical Analysis

MedKoo Cat#: 563390

Name: Ness0327

CAS#: 494844-07-4

Chemical Formula: C24H23Cl3N4O

Exact Mass: 488.0937

Molecular Weight: 489.82

Elemental Analysis: C, 58.85; H, 4.73; Cl, 21.71; N, 11.44; O, 3.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ness0327; Ness-0327; Ness 0327;
IUPAC/Chemical Name
8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydro-N-1-piperidinyl-benzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide
InChi Key
NCXBPZJQQSNIRA-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H23Cl3N4O/c25-16-7-9-18-15(13-16)5-4-6-19-22(24(32)29-30-11-2-1-3-12-30)28-31(23(18)19)21-10-8-17(26)14-20(21)27/h7-10,13-14H,1-6,11-12H2,(H,29,32)
SMILES Code
O=C(C1=NN(C2=CC=C(Cl)C=C2Cl)C3=C1CCCC4=CC(Cl)=CC=C43)NN5CCCCC5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 489.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gomis-González M, Busquets-Garcia A, Matute C, Maldonado R, Mato S, Ozaita A. Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model. Genes (Basel). 2016 Aug 31;7(9). pii: E56. doi: 10.3390/genes7090056. PubMed PMID: 27589806; PubMed Central PMCID: PMC5042387. 2: Lee SH, Ledri M, Tóth B, Marchionni I, Henstridge CM, Dudok B, Kenesei K, Barna L, Szabó SI, Renkecz T, Oberoi M, Watanabe M, Limoli CL, Horvai G, Soltesz I, Katona I. Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release. J Neurosci. 2015 Jul 8;35(27):10039-57. doi: 10.1523/JNEUROSCI.4112-14.2015. PubMed PMID: 26157003; PubMed Central PMCID: PMC4495235. 3: Kim J, Watkins BA. Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity. J Nutr Biochem. 2014 Aug;25(8):815-23. doi: 10.1016/j.jnutbio.2014.03.012. Epub 2014 Apr 4. PubMed PMID: 24854955. 4: Kim J, Carlson ME, Watkins BA. Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts. Front Physiol. 2014 Mar 21;5:100. doi: 10.3389/fphys.2014.00100. eCollection 2014. PubMed PMID: 24711795; PubMed Central PMCID: PMC3968752. 5: Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry. 2013 Dec;18(12):1294-301. doi: 10.1038/mp.2012.145. Epub 2012 Oct 16. PubMed PMID: 23070073. 6: Chiba T, Ueno S, Obara Y, Nakahata N. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. J Pharm Pharmacol. 2011 May;63(5):636-47. doi: 10.1111/j.2042-7158.2011.01250.x. Epub 2011 Mar 28. PubMed PMID: 21492165. 7: Latek D, Kolinski M, Ghoshdastider U, Debinski A, Bombolewski R, Plazinska A, Jozwiak K, Filipek S. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR. J Mol Model. 2011 Sep;17(9):2353-66. doi: 10.1007/s00894-011-0986-7. Epub 2011 Mar 2. PubMed PMID: 21365223. 8: Bertalovitz AC, Ahn KH, Kendall DA. Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. Drug Dev Res. 2010 Nov 1;71(7):404-411. PubMed PMID: 21170298; PubMed Central PMCID: PMC3003262. 9: Murineddu G, Ruiu S, Loriga G, Manca I, Lazzari P, Reali R, Pani L, Toma L, Pinna GA. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cy clohepta[1,2-c]pyrazole-3-carboxamide. J Med Chem. 2005 Nov 17;48(23):7351-62. PubMed PMID: 16279795. 10: Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S. Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. Eur J Pharmacol. 2005 Nov 21;525(1-3):150-3. Epub 2005 Nov 3. PubMed PMID: 16271359. 11: Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther. 2003 Jul;306(1):363-70. Epub 2003 Mar 27. PubMed PMID: 12663689.